微波消融联合全身化疗治疗晚期非小细胞肺癌的疗效对血清VEGF、id1蛋白浓度的影响  

Influence of the VEGF and Id1 of Microwave Ablation Combined with Systemic Chemotherapy in Treatment of Advanced Non-small Cell Lung Cancer and Its Clinical Efficacy

作　　者：戎冬文[1] 王慧宇[2] 贾军梅[1] 张革红[1] 仇海乐 张海燕[3] 

机构地区：[1]山西医科大学第一医院肿瘤科,山西太原030001 [2]首都医科大学肿瘤医学院/北京世纪坛医院超声介入科,北京100038 [3]山西医科大学第一医院科研中心,山西太原030001

出　　处：《现代生物医学进展》2017年第36期7151-7154,共4页Progress in Modern Biomedicine

基　　金：山西医科大学第一医院青年科研基金项目(YQ1201)

摘　　要：目的:探讨微波消融联合全身化疗治疗晚期非小细胞肺癌(NSCLC)患者的临床疗效及对患者血清中血管内皮生长因子(VEGF)、分化抑制因子-1(id1)蛋白浓度的影响。方法:选取2014年5月到2015年12月在我院接受治疗的晚期NSCLC患者50例,按随机数字表法分为对照组和观察组各25例,对照组给予全身化疗治疗,观察组给予微波消融联合全身化疗治疗。治疗后4周对两组的客观缓解率、临床受益率、并发症发生率进行对比,对比两组患者治疗前和治疗后4周血清中VEGF、id1蛋白浓度,对比两组患者的6个月生存率和1年生存率。结果:治疗后4周观察组客观缓解率高于对照组,但差异无统计学意义(P>0.05),观察组临床受益率显著高于对照组,差异有统计学意义(P<0.05)。治疗后4周两组患者血清中VEGF、id1蛋白浓度较治疗前均显著降低,差异有统计学意义(P<0.05),两组的id1蛋白浓度比较无统计学意义(P>0.05),观察组血清中VEGF浓度低于对照组,差异有统计学意义(P<0.05)。两组患者治疗后并发症发生率比较差异无统计学意义(P>0.05)。观察组1年生存率显著高于对照组,差异有统计学意义(P<0.05)。结论:微波消融联合全身化疗治疗晚期NSCLC患者,能有效提高患者临床受益率,更显著的降低血清中VEGF浓度,提升患者1年生存率,较单用全身化疗优势更为明显,值得临床推广应用。Objective： To explore influence of the vascular endothelial growth factor（VEGF） and inhibitor of differentiation-1（id1） of microwave ablation combined with systemic chemotherapy in treatment of advanced non-small cell lung cancer（NSCLC） and its clinical efficacy. Methods： 50 patients with advanced NSCLC in our hospital from May 2014 to December 2015 were selected, they were divided into control group and observation group as each group 25 cases by random number table method. The control group was treated with systemic chemotherapy, the observation group was treated with microwave ablation combined with systemic chemotherapy. The objective remission rate, clinical benefit rate and complication rate of the two groups were compared 4 weeks after treatment, the serum VEGF, id1 protein concentrations of the two groups were compared before and after 4 weeks treatment, the 6 month survival rate and the1 year survival rate of the two groups were compared. Results： The objective remission rate of the observation group was higher than that of the control group 4 weeks after treatment, the difference was not statistically significant（P〉0.05）, the clinical benefit rate of the observation group was significantly higher than that of the control group, the difference was statistically significant（P〈0.05）. The serum VEGF, id1 protein concentrations of the two groups 4 weeks after treatment were significantly lower those before treatment, the differences were statistically significant（P〈0.05）, the id1 protein concentrations of two groups was no significant difference（P〉0.05）, the serum VEGF concentrations of the observation group was lower than that in the control group, the difference was statistically significant（P〈0.05）. The complication rate of two groups was no significant difference（P〉0.05）. The survival rate of 1 year of the observation group was signifi-cantly higher than that in the control group, the difference was statistically significant（P〈0.05）. Conclusion�

关 键 词：微波消融 全身化疗 晚期非小细胞肺癌 血管内皮生长因子 分化抑制因子-1 疗效 

分 类 号：R734.2[医药卫生—肿瘤]